Am J Clin Oncol

1. KASHIWABARA K, Fujii S, Tsumura S, Tokunaga R, et al
   Feasibility, Tolerability, and Effectiveness of Transbronchial Interventions in Elderly Patients With Malignant Central Airway Obstruction: A Retrospective Single-institution Study.
   Am J Clin Oncol. 2024;47:223-227.
   

   >> Share

   
   

   
   Ann Surg Oncol

2. KANZAKI R, Fukuda H, Kobayashi M, Horiguchi J, et al
   Pathological Pleural Invasion is a Risk Factor for Late Recurrence in Long-Term Survivors of Non-small Cell Lung Cancer after Complete Resection.
   Ann Surg Oncol. 2024 Apr 22. doi: 10.1245/s10434-024-15279.
   

   >> Share

   
   

   
   Arch Pathol Lab Med

3. HUNG YP, Chirieac LR
   Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.
   Arch Pathol Lab Med. 2024;148:e77-e89.
   

   >> Share

   
   
4. BLAAUWGEERS H, Filipello F, Lissenberg-Witte B, Doglioni C, et al
   Loose Tumor Cells in Pulmonary Arteries of Lung Adenocarcinoma Resection Specimens: No Correlation With Survival, Despite High Prevalence.
   Arch Pathol Lab Med. 2024;148:588-594.
   

   >> Share

   
   

   
   BMC Cancer

5. SHI MX, Ding X, Tang L, Cao WJ, et al
   PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis.
   BMC Cancer. 2024;24:504.
   

   >> Share

   
   
6. SKURIKHIN E, Ermakova N, Zhukova M, Pan E, et al
   Effects of reprogrammed splenic CD8(+) T-cells in vitro and in mice with spontaneous metastatic Lewis lung carcinoma.
   BMC Cancer. 2024;24:522.
   

   >> Share

   
   
7. OKAYAMA T, Suzuki K, Morishita S, Inoue J, et al
   Correction: Pretreatment quality of life and survival in patients with lung cancer: a systematic review and meta-analysis.
   BMC Cancer. 2024;24:529.
   

   >> Share

   
   
8. GUO Y, Pan Y, Wan J, Gong B, et al
   Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review.
   BMC Cancer. 2024;24:523.
   

   >> Share

   
   

   
   Cancer Epidemiol Biomarkers Prev

9. WANG J, Wang Q, Shi Z, Yan X, et al
   Serum lipid levels, genetic risk, and lung cancer incidence: A large prospective cohort study.
   Cancer Epidemiol Biomarkers Prev. 2024.
   

   >> Share

   
   

   
   Cancer Lett

10. WANG PS, Liu Z, Sweef O, Saeed AF, et al
    Hexavalent chromium exposure activates the non-canonical nuclear factor kappa B pathway to promote immune checkpoint protein programmed death-ligand 1 expression and lung carcinogenesis.
    Cancer Lett. 2024;589:216827.
    

    >> Share

    
    
11. YU T, Liu Z, Tao Q, Xu X, et al
    Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming.
    Cancer Lett. 2024;589:216824.
    

    >> Share

    
    
12. LUO S, Luo Y, Wang Z, Yin H, et al
    Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung adenocarcinoma.
    Cancer Lett. 2024;589:216811.
    

    >> Share

    
    

    
    Clin Cancer Res

13. ZHOU R, Liu F, Zhang H, Wang D, et al
    Fraction dose escalation of hypofractionated radiotherapy with concurrent chemotherapy and subsequent consolidation immunotherapy in locally advanced non-small cell lung cancer: a phase 1 study.
    Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-23-3600.
    

    >> Share

    
    

    
    Clin Lung Cancer

14. DJUNADI TA, Oh Y, Lee J, Yu J, et al
    Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy.
    Clin Lung Cancer. 2024 Mar 16:S1525-7304(24)00036.
    

    >> Share

    
    

    
    Eur J Cancer

15. HAAKENSEN VD, Ojlert AK, Thunold S, Farooqi S, et al
    UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.
    Eur J Cancer. 2024;202:113973.
    

    >> Share

    
    
16. CAO H, Ma Z, Huang Q, Han H, et al
    Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.
    Eur J Cancer. 2024;202:113985.
    

    >> Share

    
    
17. HERTZ DL, Joerger M, Bang YJ, Mathijssen RH, et al
    Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations.
    Eur J Cancer. 2024;202:114024.
    

    >> Share

    
    
18. LAM M, Olivier T, Haslam A, Tuia J, et al
    Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis.
    Eur J Cancer. 2024;202:114019.
    

    >> Share

    
    

    
    Eur J Cardiothorac Surg

19. PRISCIANDARO E, Bertolaccini L, Fieuws S, Cara A, et al
    Multicentre retrospective analysis on pulmonary metastasectomy: an European perspective.
    Eur J Cardiothorac Surg. 2024;65:ezae141.
    

    >> Share

    
    

    
    Int J Cancer

20. RAHMAN ML, Shu XO, Jones DP, Hu W, et al
    A nested case-control study of untargeted plasma metabolomics and lung cancer among never-smoking women within the prospective Shanghai Women's Health Study.
    Int J Cancer. 2024 Apr 23. doi: 10.1002/ijc.34929.
    

    >> Share

    
    

    
    J Cancer Res Clin Oncol

21. LIU W, Zhou D, Zhang L, Huang M, et al
    Characteristics and outcomes of cancer patients admitted to intensive care units in cancer specialized hospitals in China.
    J Cancer Res Clin Oncol. 2024;150:205.
    

    >> Share

    
    
22. CHEN Y, Ji Y, Shen L, Li Y, et al
    High core 1beta1,3-galactosyltransferase 1 expression is associated with poor prognosis and promotes cellular radioresistance in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:214.
    

    >> Share

    
    
23. BILGIN B, Kuralay Y, Yucel S
    Prognostic importance of prognostic nutritional index and modified Glasgow prognostic score in advanced lung cancer with targetable mutation.
    J Cancer Res Clin Oncol. 2024;150:215.
    

    >> Share

    
    
24. TAMURA K, Okuma Y, Nomura S, Fukuda A, et al
    Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.
    J Cancer Res Clin Oncol. 2024;150:216.
    

    >> Share

    
    

    
    J Clin Oncol

25. SPIGEL DR, Dowlati A, Chen Y, Navarro A, et al
    RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
    J Clin Oncol. 2024 Apr 22:JCO2302110. doi: 10.1200/JCO.23.02110.
    

    >> Share

    
    

    
    J Thorac Oncol

26. GADGEEL SM, Rodriguez-Abreu D, Halmos B, Garassino MC, et al
    Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up.
    J Thorac Oncol. 2024 Apr 18:S1556-0864(24)00169.
    

    >> Share

    
    

    
    JAMA Oncol

27. NORONHA V, Patil V, Menon N, Shah M, et al
    Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer-Long-Term Results of a Randomized Clinical Trial.
    JAMA Oncol. 2024 Apr 25. doi: 10.1001/jamaoncol.2024.0584.
    

    >> Share

    
    

    
    Lung Cancer

28. ZHANG SL, Tian Y, Yu J, Zhang JH, et al
    Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis.
    Lung Cancer. 2024;191:107799.
    

    >> Share

    
    
29. OKAHISA M, Udagawa H, Matsumoto S, Kato T, et al
    Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia.
    Lung Cancer. 2024;191:107798.
    

    >> Share

    
    

    
    Nat Med

30. VAIDYA A, Chen RJ, Williamson DFK, Song AH, et al
    Demographic bias in misdiagnosis by computational pathology models.
    Nat Med. 2024;30:1174-1190.
    

    >> Share

    
    
31. SINGHAL A, Li BT, O'Reilly EM
    Targeting KRAS in cancer.
    Nat Med. 2024;30:969-983.
    

    >> Share

    
    
32. GHILARDI G, Fraietta JA, Gerson JN, Van Deerlin VM, et al
    T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
    Nat Med. 2024;30:984-989.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share